Safety Study of GSK Biologicals' Rotarix (Rotavirus Vaccine, Live, Oral) Administered to a Birth Cohort in United States Health Insurance Plans.

Trial Profile

Safety Study of GSK Biologicals' Rotarix (Rotavirus Vaccine, Live, Oral) Administered to a Birth Cohort in United States Health Insurance Plans.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs RIX 4414 (Primary) ; Poliovirus vaccine inactivated
  • Indications Poliomyelitis; Rotavirus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 26 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 26 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top